$64.61
+0.79 (+1.24%)
Last updated: Apr 16, 2026 00:45
Fundamentals Overview
Boston Scientific Corporation is near the low of its 52-week range with premium valuation, trading relatively flat today.
Valuation premium
Intrinsic value (DCF)
+11.5% upside vs price
Profitability
Risk (Beta)
0.78 — lower vol
Earnings & growth
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
DCF +11.5% upside vs price · Analyst grade: B
Pressures (Sell):
Sentiment weakening (1 downgrade) · 3M vs S&P 500: -33.2% · 3M vs Healthcare sector: -26.4%
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: B. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 18, Outperform: 8, Overweight: 4.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $72.01; current price is $64.61. That’s a +11.5% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | 33.44 |
| DCF value (model) | $72.01 (11.5% upside) |
| PEG (TTM) | 0.6 |
| P/B (TTM) | 3.95 |
| P/S (TTM) | 4.78 |
| P/FCF (TTM) | 26.49 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 1.62 |
| Quick Ratio (TTM) | 1.08 |
| Cash Ratio (TTM) | 0.38 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 14.4% |
| Gross margin (TTM) | 69.01% |
| Operating margin (TTM) | 19.78% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for BSX.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Citigroup | maintain | Buy | Buy | 2026-04-07 |
| Evercore ISI Group | maintain | Outperform | Outperform | 2026-04-06 |
| Raymond James | downgrade | Strong Buy | Outperform | 2026-03-30 |
| RBC Capital | maintain | Outperform | Outperform | 2026-03-30 |
| Needham | maintain | Buy | Buy | 2026-03-30 |
| Goldman Sachs | maintain | Buy | Buy | 2026-03-27 |
| Needham | maintain | Buy | Buy | 2026-03-20 |
| Stifel | maintain | Buy | Buy | 2026-03-20 |
| Truist Securities | maintain | Buy | Buy | 2026-03-18 |
| UBS | maintain | Buy | Buy | 2026-03-17 |
| Citigroup | maintain | Buy | Buy | 2026-03-11 |
| Canaccord Genuity | maintain | Buy | Buy | 2026-02-17 |
| BTIG | maintain | Buy | Buy | 2026-02-09 |
| Citigroup | maintain | Buy | Buy | 2026-02-05 |
| RBC Capital | maintain | Outperform | Outperform | 2026-02-05 |
| Baird | maintain | Outperform | Outperform | 2026-02-05 |
| UBS | maintain | Buy | Buy | 2026-02-05 |
| Mizuho | maintain | Outperform | Outperform | 2026-02-05 |
| Morgan Stanley | maintain | Overweight | Overweight | 2026-02-05 |
| Stifel | maintain | Buy | Buy | 2026-02-05 |
| JP Morgan | maintain | Overweight | Overweight | 2026-02-05 |
| Wells Fargo | maintain | Overweight | Overweight | 2026-02-05 |
| Truist Securities | maintain | Buy | Buy | 2026-02-05 |
| Canaccord Genuity | maintain | Buy | Buy | 2026-02-05 |
| Needham | maintain | Buy | Buy | 2026-02-05 |
| TD Cowen | maintain | Buy | Buy | 2026-02-05 |
| Evercore ISI Group | maintain | Outperform | Outperform | 2026-02-05 |
| BTIG | maintain | Buy | Buy | 2026-02-04 |
| Barclays | maintain | Overweight | Overweight | 2026-02-03 |
| Oppenheimer | maintain | Outperform | Outperform | 2026-01-16 |